From the newsletter
Africa has spent the past few years building the capacity to manufacture more of its own health products. Yet despite notable progress, manufacturers cannot fully utilise their capacity because the market is not large and predictable enough to sustain investment. New developments in Ghana and Uganda suggest pooled procurement is moving to solve this.
Uganda’s Dei BioPharma has been approved as a supplier under the African Pooled Procurement Mechanism, giving the manufacturer a route to compete for aggregated demand beyond its domestic market. The company has 40 products approved for manufacture and 14 for sale.
Ghana has joined the mechanism, giving its vaccine and pharmaceutical manufacturers access to aggregated demand from 55 African Union member states. The country is also developing advance purchase commitments to give manufacturers greater visibility over future orders.
More details